Abstract:Background This study aimed to understand the clinical characteristics and outcomes of children with Langerhans cell histiocytosis (LCH) in China. Methods We conducted a retrospective study of 95 paediatric patients with LCH in West China Second University Hospital of Sichuan University between July 2013 and August 2020. Results The onset age of multisystem LCH (MS-LCH) patients with risk organ (RO) involvement was younger than that of MS-LCH without RO involvement (p = .002) and single system LCH (p < .001) patients; bone was the most frequently involved organ, followed by the skin. Of all, the BRAF-V600E mutation was detected in 48 out of 84 patients who underwent gene analysis. Additionally, in our study, BRAF p.N486_T491 > K, BRAF p.L485_P490delinsF, BRAF p.R506_K507insLLR, ARAF p.Q349_F351delinsL and MAP2K1 p.Q58_E62del were known mutations in the mitogen-activated protein kinase (MAPK) pathway. The BRAF-V600E genotype in the tissue and plasma prior to therapy were detected in 16 patients, and the concordance was only 37.5% (6/16). According to the modified LCH-III-based-protocol, JLSG-02 protocol chemotherapy, and vemurafenib, the estimated five-year overall survival, event-free survival (EFS) and cumulative reactivation rates of 95 patients were 98.8%, 74.6% and 24.5%, respectively. The EFS rate in good responders was better than that in poor responders at 12-week (HR = 0.022, 95%CI 0.002-0.231, p = .002), and EFS was not affected by age, RO involvement or BRAF-V600E mutation. Regarding sequelae, nine patients had central diabetes insipidus and two had growth retardation. Conclusions In this study, LCH was a highly heterogeneous disease characterized molecularly by MAPK-pathway activating mutations. Vincristine, prednisone and cytarabine-based chemotherapy combined with vemurafenib improved the prognosis of childhood LCH. In future, prospective clinical trials and novel therapeutic strategies should be developed to improve outcomes in paediatric patients with LCH. KEY MESSAGE Children with Langerhans cell histiocytosis in China present highly heterogeneous clinical characteristics, with up to 60% of cases harbouring mutations in MAPK pathway. Treatment response at 12-week is associated with EFS in our study. Vincristine, prednisone and cytarabine-based chemotherapy combined with vemurafenib improved the prognosis of Chinese childhood LCH, but the reactivation rate is still high.

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis

Effectiveness and safety of Dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated LCH

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF V 600 E-Mutated Langerhans Cell Histiocytosis

BRAF V600E Mutation in Pediatric Langerhans Cell Histiocytosis and its Clinical Significance

EP08.02-052 Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients with BRAF V600E- Mutation Positive Metastatic NSCLC

[BRAF-V600E Mutation and Its Clinical Significance in Children with Langerhans Cell Histiocytosis].

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

BRAF V600E Mutation in Cell-Free DNA, Rather Than in Lesion Tissues, at Diagnosis is an Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis.

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study

Clinical Features and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis.

Clinical and Prognostic Characteristics of 95 Cases of Langerhans Cell Histiocytosis in Children: a Single-Institute Experience from 2013 to 2020

Data from <i>braf</i><sup>v600e</sup> Mutation in Cell-Free DNA, Rather Than in Lesion Tissues, at Diagnosis is an Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis

Dramatic Efficacy of Dabrafenib in Erdheim-Chester Disease (ECD): a Pediatric Patient with Multiple Large Intracranial ECD Lesions Hidden by Refractory Langerhans Cell Histiocytosis.

BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report